Source: Breast Cancer Research and Treatment. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, CO-TERAPIA, QUIMIOTERÁPICOS
ABNT
BONADIO, Renata Colombo et al. Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study. Breast Cancer Research and Treatment, v. 211, n. 1, p. 131-137, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/84902. Acesso em: 04 dez. 2025.APA
Bonadio, R. C., Tavares, M. C., Balint, F. C., Sousa, I. M. de, Comini, A. C. M., Madasi, F., et al. (2025). Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study. Breast Cancer Research and Treatment, 211( 1), 131-137. doi:10.1007/s10549-025-07628-3NLM
Bonadio RC, Tavares MC, Balint FC, Sousa IM de, Comini ACM, Madasi F, Bines J, Ferreira RDP, Rosa DD, Hoff PMG. Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study [Internet]. Breast Cancer Research and Treatment. 2025 ; 211( 1): 131-137.[citado 2025 dez. 04 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84902Vancouver
Bonadio RC, Tavares MC, Balint FC, Sousa IM de, Comini ACM, Madasi F, Bines J, Ferreira RDP, Rosa DD, Hoff PMG. Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study [Internet]. Breast Cancer Research and Treatment. 2025 ; 211( 1): 131-137.[citado 2025 dez. 04 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84902

